Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Platteau, P.
Right arrow Articles by Liebaers, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Platteau, P.
Right arrow Articles by Liebaers, I.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 17, No. 11, 2807-2812, November 2002
© 2002 European Society of Human Reproduction and Embryology

Preimplantation genetic diagnosis for fragile Xa syndrome: difficult but not impossible

Peter Platteau1,3, Karen Sermon2, Sara Seneca2, André Van Steirteghem1, Paul Devroey1 and Inge Liebaers2

1 Centres for Reproductive Medicine and 2 Medical Genetics, University Hospital and Medical school, Dutch-speaking Brussels Free University, Laarbeeklaan 101, 1090 Brussels, Belgium

BACKGROUND: In this paper, we review our clinical preimplantation genetic diagnosis (PGD) programme for fragile Xa syndrome, analysing if PGD for these couples is still a valuable option, as it is particularly difficult for two reasons. First, the couples have to be informative (the number of triplet repeats on the healthy FMR-1 allele of the mother has to be different from the number of repeats on the healthy FMR-1 allele of the father) and second, women with a premutation are at increased risk of premature ovarian failure. METHODS: A total of 34 couples attended our genetics department between December 1998 and July 2001, requesting information about PGD for fragile Xa syndrome. RESULTS: Eight couples decided not to go further with the procedure and of the 26 remaining couples, 16 were informative (61.5%). Four couples have so far not started ovarian stimulation, one patient was totally refractive to stimulation and 11 couples have had a total of 19 oocyte retrievals. From these, there have been 13 embryo transfers with a clinical pregnancy rate per embryo transfer of 23%; the implantation rate was 13.6% and the live birth rate per couple was 27.3%. CONCLUSIONS: PGD for fragile Xa is feasible for a number of couples. A pre-PGD work-up should include a determination of the premutation or mutation carrier status, the maternal or paternal origin of the premutation and an estimation of the ovarian reserve of the patient. Fragile Xa premutation carriers should be advised not to postpone reproduction for too long.

Key words: controlled ovarian stimulation/fragile X syndrome/preimplantation genetic diagnosis/premature ovarian failure/premutation

3 To whom correspondence should be addressed. E-mail: peter.platteau{at}az.vub.ac.be


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
NEJMHome page
L. M. Nelson
Primary Ovarian Insufficiency
N. Engl. J. Med., February 5, 2009; 360(6): 606 - 614.
[Full Text] [PDF]


Home page
Mol Hum ReprodHome page
P. Burlet, N. Frydman, N. Gigarel, V. Kerbrat, G. Tachdjian, E. Feyereisen, J.-P. Bonnefont, R. Frydman, A. Munnich, and J. Steffann
Multiple displacement amplification improves PGD for fragile X syndrome
Mol. Hum. Reprod., October 1, 2006; 12(10): 647 - 652.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K. Stouffs, W. Lissens, H. Tournaye, A. Van Steirteghem, and I. Liebaers
The choice and outcome of the fertility treatment of 38 couples in whom the male partner has a Yq microdeletion
Hum. Reprod., July 1, 2005; 20(7): 1887 - 1896.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
C. Spits, M. De Rycke, N. Van Ranst, H. Joris, W. Verpoest, W. Lissens, P. Devroey, A. Van Steirteghem, I. Liebaers, and K. Sermon
Preimplantation genetic diagnosis for neurofibromatosis type 1
Mol. Hum. Reprod., May 1, 2005; 11(5): 381 - 387.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
M. De Rycke, I. Georgiou, K. Sermon, W. Lissens, P. Henderix, H. Joris, P. Platteau, A. Van Steirteghem, and I. Liebaers
PGD for autosomal dominant polycystic kidney disease type 1
Mol. Hum. Reprod., January 1, 2005; 11(1): 65 - 71.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.